BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease.
Our mission is to improve quality of life for patients suffering from Central Nervous System (CNS) disorders. Patients with neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease will be treated with antibodies targeting the misfolded proteins in these disorders.
Our technology is now applied to other CNS disorders like Parkinson’s disease, and novel antibodies are being developed.
BioArctic has a proprietary technology by which therapeutic monoclonal antibodies can be developed. These antibodies are highly selective for aggregated/misfolded proteins involved in disorders such as Alzheimer’s disease and Parkinson’s disease.
The key molecular event in these diseases is today believed to be protein misfolding and aggregation. The spreading of soluble aggregates leads to dysfunction of the nerve cells, cell death, brain damage and symptoms of disease. Each neurodegenerative disorder is characterized through its unique aggregated protein. The hallmark of Alzheimer’s disease is amyloid-beta, whereas alpha-synuclein is the signature protein of Parkinson’s disease. An attractive treatment strategy is to eliminate these toxic proteins.
The antibodies developed by BioArctic have the unique property to reduce the levels of the soluble, toxic aggregated/misfolded proteins (oligomers/protofibrils) in the brain. Reduction of these toxic proteins is believed to be of significant clinical value.
Blood-brain barrier technology
The blood-brain barrier controls the exchange of substances between the blood and the brain. It protects the brain from toxins and pathogens, but at the same time it can make the delivery of therapeutic agents to the brain more difficult. BioArctic and research groups at Uppsala University in Sweden are collaborating on developing technology that facilitates the passage of antibodies across the blood-brain barrier.
The research, which is at an early stage, has shown highly encouraging results and the technology has significant potential in the treatment of several different diseases of the brain. During 2019 BioArctic increased activities in this area and added further expertise.